ClinicalTrials.gg

Program

ombetoxabart

Its studies are mostly in Clostridium Infections, led by AstraZeneca.

Furthest: phase 2, since Nov 20, 20253 company-led studies, 1 open or runningNext primary completion: Apr 20, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca31 open or runningphase 2since Nov 20, 2025Jun 17, 2024Apr 20, 2027phase 2 · NCT07285213
  • Named in AstraZeneca’s own pipeline as AZD5148, phase 2, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 17, 2024First study: phase 1 study in Clostridium InfectionsFirst studyNCT06469151 · 84 enrolled · United States
  2. Oct 4, 2024Phase 1 study in Clostridium InfectionsNCT06639997 · 16 enrolled · Japan
  3. Nov 20, 2025Phase 2 study in Clostridium InfectionsPhase 2 reachedNCT07285213 · 230 planned · United States, Australia, Canada and more

Ahead

  1. Apr 20, 2027Primary completion: phase 2 study in Clostridium InfectionsNCT07285213

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07285213Clostridium Infections · United States, Australia, Canada and more2RecruitingApr 20, 2027230
NCT06639997Clostridium Infections · Japan1CompletedDec 25, 202516
NCT06469151Clostridium Infections · United States1CompletedOct 22, 202584

How it is read

Names in the registry

  • “AZD5148”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.